Skip to main content
Caplight Logo









Ablaze Pharmaceuticals

Ablaze Pharmaceuticals

Private
ShanghaiHealthcare & Life Scienceshttps://ablazepharma.com

Last Round

Series A

Nov 29, 2021

Total Funding Raised

$75M

Company Overview

Ablaze Pharmaceuticals is a biopharmaceutical company specializing in the development of Targeted Radiotherapy (TRT) treatments for cancer patients in the Chinese market.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

targeted radiopharmaceutical therapiesTRTradiopharmaradioligand therapyGPC3 targeted therapyliver cancer treatmentclinical-stage biopharmadrug in-licensingoncologyactinium-225 therapylutetium-177 therapyalpha emitter therapynuclear medicinesolid tumor therapyChina healthcare market

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ablaze Pharmaceuticals Comparables

Compare Ablaze Pharmaceuticals with similar companies based on industry and business-model similarity.

Ablaze Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AlphaGen Therapeutics
89%
C-Ray Therapeutics
88%
Yantai Lannacheng Biotechnology Co., Ltd.
84%

Ablaze Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 29, 2021

Key People

Founding team and executive leadership

Alan Xu

Co-Founder And Chief Operating Officer

Founding Team

Ablaze Pharmaceuticals Investors

Notable investors and investment history

Ablaze Pharmaceuticals investors
InvestorRounds
Nan Fung Life SciencesSeries A
Advantech CapitalSeries A
Nan Fung GroupSeries A
venBioSeries A
VenrockSeries A
Samsara BioCapitalSeries A
Vivo CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 29, 2021

    $75M round led by Vivo Capital and Advantech Capital.

Ablaze Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ablaze Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ablaze Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range3
Year Founded2021
Last FundingNov 29, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?